B. Braun has agreed to pay $4.8 million in penalties and $3 million in restitution to settle with the U.S. Justice Department over criminal complaints related to contaminated pre-filled saline flush syringes sold in 2007.
The syringes, which infected patients in multiple U.S. states, were actually made by a supplier, AM2PAT, but B. Braun’s brand name was on them.
“The Federal Food, Drug and Cosmetic Act prohibits companies from selling contaminated products, even when the company did not make the product itself,” Benjamin C. Mizer, head of the Justice Department’s Civil Division, said in a news release.
The syringes, which infected patients in multiple U.S. states, were actually made by a supplier, AM2PAT, but B. Braun’s brand name was on them.
“The Federal Food, Drug and Cosmetic Act prohibits companies from selling contaminated products, even when the company did not make the product itself,” Benjamin C. Mizer, head of the Justice Department’s Civil Division, said in a news release.
